RedHill Biopharma Enters At-the-Market Offering Agreement
Ticker: RDHL · Form: 6-K · Filed: Feb 3, 2025 · CIK: 1553846
| Field | Detail |
|---|---|
| Company | Redhill Biopharma Ltd. (RDHL) |
| Form Type | 6-K |
| Filed Date | Feb 3, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $3,464,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: at-the-market offering, capital raise, equity
Related Tickers: RHBP
TL;DR
RHBP inked an ATM deal with H.C. Wainwright to sell ADSs.
AI Summary
On February 3, 2025, RedHill Biopharma Ltd. entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC. This agreement allows the company to offer and sell its American Depositary Shares (ADSs) through Wainwright as its sales agent.
Why It Matters
This agreement provides RedHill Biopharma with a flexible way to raise capital by selling its shares directly into the market as needed.
Risk Assessment
Risk Level: medium — At-the-market offerings can dilute existing shareholders' value if not managed carefully, and the success depends on market conditions and investor demand.
Key Numbers
- 10,000 — ADS Ratio (Each American Depositary Share represents ten thousand ordinary shares.)
Key Players & Entities
- RedHill Biopharma Ltd. (company) — Registrant
- H.C. Wainwright & Co., LLC (company) — Sales Agent
- February 3, 2025 (date) — Date of Agreement
FAQ
What type of offering did RedHill Biopharma enter into?
RedHill Biopharma entered into an at-the-market offering agreement.
Who is the sales agent for this offering?
H.C. Wainwright & Co., LLC is the sales agent for the offering.
On what date was the agreement signed?
The agreement was entered into on February 3, 2025.
What securities can be offered and sold under this agreement?
American Depositary Shares (ADSs) can be offered and sold.
How many ordinary shares does each ADS represent?
Each ADS represents ten thousand (10,000) ordinary shares.
Filing Stats: 498 words · 2 min read · ~2 pages · Grade level 7.4 · Accepted 2025-02-03 16:28:23
Key Financial Figures
- $3,464,000 — ng an aggregate offering price of up to $3,464,000. Attached hereto and incorporated by r
Filing Documents
- zk2532631.htm (6-K) — 12KB
- exhibit_1-1.htm (EX-1.1) — 220KB
- exhibit_5-1.htm (EX-5.1) — 11KB
- exhibit_5-2.htm (EX-5.1) — 11KB
- image0.jpg (GRAPHIC) — 155KB
- image00003.jpg (GRAPHIC) — 7KB
- image00004.jpg (GRAPHIC) — 14KB
- image00006.jpg (GRAPHIC) — 5KB
- 0001178913-25-000301.txt ( ) — 503KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: February 3, 2025 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer